Octreotide-assisted endoscopy versus octreotide-assisted TIPS for acute esophagogastric variceal bleeding with and without terlipressin intensification: A real-world study

When the liver becomes scarred and stiff, a condition known as cirrhosis, the blood flowing through it meets a wall of resistance. This pressure builds up in the veins that carry blood from the digestive organs, causing them to swell and bulge like overfilled balloons. These swollen veins, called varices, sit in the esophagus and stomach, waiting for a moment of weakness. When they burst, they cause a sudden, life-threatening flood of blood into the digestive tract. This event, known as acute esophagogastric variceal bleeding, is a leading cause of death for people with advanced liver disease. The medical community has long relied on two main strategies to stop the bleeding: using a camera to look inside the body and seal the broken vessels, or using a specialized tube to create a new channel that bypasses the liver entirely to lower the pressure. For years, doctors have also added a second, stronger medication to these treatments, hoping that a double dose of pressure-lowering drugs would provide better protection. But until now, no one had clearly compared the long-term safety and effectiveness of the camera approach against the tube approach, nor had they confirmed whether adding that extra medication actually helps or simply adds risk.

A team of researchers at Tangdu Hospital in Xi'an, China, set out to answer these questions by looking back at the records of 656 patients who suffered this type of bleeding between 2017 and 2025. They focused on two primary treatment paths. The first path involved giving patients a drug called octreotide to slow blood flow, followed immediately by an endoscopic procedure. In this procedure, a doctor uses a flexible tube with a camera to find the bleeding vein and either injects a glue-like substance to seal it or applies a sclerosing agent to irritate the vessel wall and close it off. The second path also started with octreotide but then moved to a more invasive procedure called a transjugular intrahepatic portosystemic shunt, or TIPS. In this intervention, a radiologist threads a catheter through a vein in the neck to place a small metal stent inside the liver, creating a shortcut that diverts blood away from the high-pressure area. Some of these patients also received a second drug, terlipressin, which is a potent vasoconstrictor, intended to tighten blood vessels even further. The researchers wanted to see which approach kept patients from bleeding again and which approach kept them alive.

The study revealed a clear distinction between the two methods regarding the prevention of future bleeding. Patients who received the TIPS procedure were significantly less likely to experience a rebleeding event within six weeks compared to those who received the endoscopic treatment. This advantage held true even for the long term, with the TIPS group showing a much lower risk of bleeding again after the initial six-week period. The benefit was particularly strong for patients who were already in poor health, those who had lost a large amount of blood, and those without a blood clot in their main liver vein. However, despite this superior ability to stop the bleeding from returning, the TIPS procedure did not lower the risk of death within the first six weeks. Patients who underwent the invasive shunt procedure were just as likely to survive as those who received the camera-based treatment. The researchers noted that while the shunt was excellent at preventing the veins from bursting again, it carried its own risks, including a higher chance of developing hepatic encephalopathy, a condition where toxins build up in the brain because the liver is bypassed, leading to confusion and altered mental states.

The investigation into the use of the second medication, terlipressin, yielded a surprising and cautionary result. The researchers compared patients who received the standard treatment with those who had terlipressin added to their regimen. They found that adding this extra drug provided no additional benefit in preventing rebleeding or saving lives. In fact, for patients who received the TIPS procedure, adding terlipressin was associated with a higher risk of negative outcomes, including a combined risk of rebleeding or death. The data suggested that the extra medication did not strengthen the treatment but instead introduced new dangers, such as abdominal pain and temporary spikes in blood pressure. The study also highlighted that the timing of the initial endoscopic procedure mattered; performing the camera examination within six to twenty-four hours after the bleeding started was linked to a lower risk of adverse events, reinforcing the importance of acting quickly once a patient is stable.

Ultimately, this large-scale review of real-world patient data suggests that the choice between a camera-based seal and a liver bypass depends heavily on the specific risks a patient faces. While the bypass procedure is more effective at preventing the veins from bleeding again, it does not improve survival rates and introduces different complications. The addition of a second, stronger drug to either treatment plan appears unnecessary and potentially harmful. The findings indicate that doctors should carefully weigh the immediate need to stop bleeding against the long-term risks of the procedure, rather than assuming that more aggressive medication or more invasive intervention will always lead to a better outcome. For patients with severe liver disease, the best path forward is a prompt, tailored decision based on their individual condition, avoiding the routine use of extra medications that offer no proven advantage.